DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
PF-05212377
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease
Serotonin 6 (5-HT6) receptor antagonist
PF-05212377
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
POL6326
2
Protein
Investigational
Unknown
Unknown
Unknown
Unknown
POL6326
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DHAP
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
DHAP
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DEPATUXIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Adenocarcinoma
Epidermal growth factor receptor erbB1 inhibitor
DEPATUXIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
W984C353CG
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BRIVOLIGIDE
2
Unknown
Investigational
Unknown
Unknown
Pain
Unknown
BRIVOLIGIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
O32A9ET2M7
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AVISCUMINE
2
Protein
Investigational
Unknown
Unknown
Melanoma
Unknown
AVISCUMINE
×
Maximum Phase:
2
First Approval:
None
UNII:
4B18YVW82N
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TOREFORANT TARTRATE
2
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Arthritis, Rheumatoid; Asthma; Psoriasis
Unknown
TOREFORANT TARTRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
HSV17TLD9C
Molecule Type:
Small molecule
Molecular Formula:
C50H70N12O6
Molecular Weight:
935.19
AlogP:
4.48
PSA:
69.73
HBD:
2.0
HBA:
#RotB:
6.0
Source:
AZD-8871
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
AZD-8871
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TRAXOPRODIL
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder, Major; Parkinson Disease; Stroke
Glutamate NMDA receptor; GRIN1/GRIN2B antagonist
TRAXOPRODIL
×
Maximum Phase:
2
First Approval:
None
UNII:
UTC046R5HM
Molecule Type:
Small molecule
Molecular Formula:
C20H25NO3
Molecular Weight:
327.42
AlogP:
2.8
PSA:
63.93
HBD:
3.0
HBA:
#RotB:
4.0
Source:
GLPG-0974
2
Small molecule
Investigational
Unknown
Unknown
Colitis, Ulcerative
Free fatty acid receptor 2 antagonist
GLPG-0974
×
Maximum Phase:
2
First Approval:
None
UNII:
X7REK61AIS
Molecule Type:
Small molecule
Molecular Formula:
C25H25ClN2O4S
Molecular Weight:
485.01
AlogP:
5.05
PSA:
77.92
HBD:
1.0
HBA:
#RotB:
8.0
Source:
HBM9161
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
HBM9161
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
C-1311
2
Small molecule
Investigational
Unknown
Unknown
Unknown
DNA topoisomerase II inhibitor
C-1311
×
Maximum Phase:
2
First Approval:
None
UNII:
MZ4Y5H4OAB
Molecule Type:
Small molecule
Molecular Formula:
C20H22N4O2
Molecular Weight:
350.42
AlogP:
2.9
PSA:
69.87
HBD:
2.0
HBA:
#RotB:
6.0
Source:
HEMIN
2
Small molecule
Investigational
Unknown
Unknown
Coproporphyria, Hereditary; Myelodysplastic Syndromes; Pancreatitis; Porphyria, Acute Intermittent; Porphyrias
Unknown
HEMIN
×
Maximum Phase:
2
First Approval:
None
UNII:
743LRP9S7N
Molecule Type:
Small molecule
Molecular Formula:
C34H32ClFeN4O4
Molecular Weight:
651.95
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
LY2624803
2
Small molecule
Investigational
Unknown
Unknown
Sleep Initiation and Maintenance Disorders
Histamine H1 receptor antagonist
LY2624803
×
Maximum Phase:
2
First Approval:
None
UNII:
63J9EQ81YC
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ACT-709478
2
Small molecule
Investigational
Unknown
Unknown
Epilepsy, Reflex
Voltage-gated T-type calcium channel blocker
ACT-709478
×
Maximum Phase:
2
First Approval:
None
UNII:
3Z7U1U8Z9E
Molecule Type:
Small molecule
Molecular Formula:
C22H18F3N5O
Molecular Weight:
425.41
AlogP:
3.97
PSA:
83.6
HBD:
1.0
HBA:
#RotB:
6.0
Source:
DAGROCORAT
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Glucocorticoid receptor modulator
DAGROCORAT
×
Maximum Phase:
2
First Approval:
None
UNII:
OPM23UN90U
Molecule Type:
Small molecule
Molecular Formula:
C29H29F3N2O2
Molecular Weight:
494.56
AlogP:
6.16
PSA:
62.22
HBD:
2.0
HBA:
#RotB:
4.0
Source:
FIPAMEZOLE
2
Small molecule
Investigational
Unknown
Unknown
Parkinson Disease
Adrenergic receptor alpha-2 antagonist
FIPAMEZOLE
×
Maximum Phase:
2
First Approval:
None
UNII:
T5RCK09KHV
Molecule Type:
Small molecule
Molecular Formula:
C14H15FN2
Molecular Weight:
230.29
AlogP:
3.0
PSA:
28.68
HBD:
1.0
HBA:
#RotB:
2.0
Source:
DANVATIRSEN
2
Oligonucleotide
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell
STAT-3 mRNA 3'UTR antisense inhibitor
DANVATIRSEN
×
Maximum Phase:
2
First Approval:
None
UNII:
31N550RD05
Molecule Type:
Oligonucleotide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ASK-8007
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Osteopontin inhibitor
ASK-8007
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DAVALINTIDE
2
Protein
Investigational
Unknown
Unknown
Obesity
Amylin receptor AMY1, CALCR/RAMP1 agonist
DAVALINTIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
668U999F9T
Molecule Type:
Protein
Molecular Formula:
C152H248N50O49S2
Molecular Weight:
3624.09
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
DERSIMELAGON
2
Small molecule
Investigational
Unknown
Unknown
Kidney Diseases; Liver Diseases; Scleroderma, Diffuse
Unknown
DERSIMELAGON
×
Maximum Phase:
2
First Approval:
None
UNII:
1CWH5SV4G2
Molecule Type:
Small molecule
Molecular Formula:
C36H45F4N3O5
Molecular Weight:
675.76
AlogP:
5.95
PSA:
82.55
HBD:
1.0
HBA:
#RotB:
9.0
Source:
METHYLPREDNISONE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
METHYLPREDNISONE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DAVANAT
2
Unknown
Investigational
Unknown
Unknown
Melanoma; Colorectal Neoplasms
Galectin-1 inhibitor
DAVANAT
×
Maximum Phase:
2
First Approval:
None
UNII:
C2BXC3OWPA
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RASDEGAFUSP ALFA
2
Protein
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma
Unknown
RASDEGAFUSP ALFA
×
Maximum Phase:
2
First Approval:
None
UNII:
SU9AMV39DB
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FIMAPORFIN
2
Unknown
Investigational
Unknown
Unknown
Neoplasms; Cholangiocarcinoma
Photosensitiser
FIMAPORFIN
×
Maximum Phase:
2
First Approval:
None
UNII:
3UVT27C76J
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ELND005
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ELND005
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
INARIGIVIR SOPROXIL
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis B, Chronic
Unknown
INARIGIVIR SOPROXIL
×
Maximum Phase:
2
First Approval:
None
UNII:
365052M0DK
Molecule Type:
Small molecule
Molecular Formula:
C25H34N7O13PS
Molecular Weight:
703.62
AlogP:
0.27
PSA:
263.69
HBD:
4.0
HBA:
#RotB:
13.0
Source:
SENAPARIB
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Small Cell Lung Carcinoma; Ovarian Neoplasms
Unknown
SENAPARIB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C24H20F2N6O3
Molecular Weight:
478.46
AlogP:
1.77
PSA:
104.19
HBD:
1.0
HBA:
#RotB:
4.0
Source:
AZD2516
2
Small molecule
Investigational
Unknown
Unknown
Gastroesophageal Reflux
Metabotropic glutamate receptor 5 negative allosteric modulator
AZD2516
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ALANOSINE
2
Small molecule
Investigational
Unknown
Unknown
Central Nervous System Neoplasms
Unknown
ALANOSINE
×
Maximum Phase:
2
First Approval:
None
UNII:
2CNI71214Y
Molecule Type:
Small molecule
Molecular Formula:
C3H7N3O4
Molecular Weight:
149.11
AlogP:
-1.23
PSA:
116.22
HBD:
3.0
HBA:
#RotB:
4.0
Source:
RHUBARB
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
RHUBARB
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AVIPTADIL
2
Protein
Investigational
Unknown
Unknown
Acute Lung Injury; Respiratory Distress Syndrome; Severe Acute Respiratory Syndrome
Adrenergic receptor alpha antagonist
AVIPTADIL
×
Maximum Phase:
2
First Approval:
None
UNII:
A67JUW790C
Molecule Type:
Protein
Molecular Formula:
C145H232N40O43S
Molecular Weight:
3255.75
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
BO-653
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BO-653
×
Maximum Phase:
2
First Approval:
None
UNII:
2VSP9T5LRX
Molecule Type:
Small molecule
Molecular Formula:
C26H44O2
Molecular Weight:
388.64
AlogP:
7.82
PSA:
29.46
HBD:
1.0
HBA:
#RotB:
8.0
Source:
CRIDANIMOD
2
Small molecule
Investigational
Unknown
Unknown
Endometrial Neoplasms
Unknown
CRIDANIMOD
×
Maximum Phase:
2
First Approval:
None
UNII:
X91E9EME19
Molecule Type:
Small molecule
Molecular Formula:
C15H11NO3
Molecular Weight:
253.26
AlogP:
2.24
PSA:
59.3
HBD:
1.0
HBA:
#RotB:
2.0
Source:
SODELGLITAZAR
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2; Metabolic Syndrome
Peroxisome proliferator-activated receptor agonist
SODELGLITAZAR
×
Maximum Phase:
2
First Approval:
None
UNII:
6G973E04VI
Molecule Type:
Small molecule
Molecular Formula:
C23H21F4NO3S2
Molecular Weight:
499.55
AlogP:
7.12
PSA:
59.42
HBD:
1.0
HBA:
#RotB:
7.0
Source:
1
2
…
174
175
176
177
178
179
180
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA